Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Relationship Among Clinically Obtained Biomarkers of Inflammation, Hypercoagulability, and Macrophage Activation, and Delirium in Critically Ill Patients With COVID-19
Khan, Sikandar , Perkins, Anthony J. , Chi, Rosalyn , Seyffert, Sarah , Conrad, Peter, Gao, Sujuan , Khan, Babar , Lindroth, Heidi , Wang, Sophia , Mulkey, Malissa

Mayo Clinic

Critical Care Explorations | January 26, 2023 | Volume: 5 | Issue: 1 | Pages: e0851

10.1097/cce.0000000000000851 | PMID 36699256 Get It

OBJECTIVES: Critically ill patients with COVID-19 experience high rates of delirium and coma. Whether delirium occurs through novel mechanisms in COVID-19 is not known. We analyzed the relationship among biomarkers of inflammation (C-reactive protein [CRP]), hypercoagulability (d-dimer), and lung macrophage activation (ferritin), and the primary composite outcome of delirium/coma next day. We also measured associations between biomarkers and next day delirium and coma independently, and delirium severity. DESIGN: Retrospective, observational cohort study. SETTING: ICUs at two large, urban, academic referral hospitals. PATIENTS: All consecutive adult patients admitted to the ICU from March 1, 2020, to June 7, 2020, with COVID-19 with clinical biomarkers and delirium assessments performed. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Daily concentrations of CRP, d-dimer, and ferritin were obtained. Coma (assessed by Richmond Agitation-Sedation Scale) and delirium (assessed by Confusion Assessment Method for the ICU/Confusion Assessment Method for the ICU-7) were measured bid. A cohort of 197 ICU patients with COVID-19 were included. Higher d-dimer (odds ratio [OR], 1.57; 95% CI, 1.17–2.12; p < 0.01) and ferritin quartiles (OR, 1.36; 95% CI, 1.02–1.81; p < 0.01) were associated with greater odds of the composite outcome of delirium/coma next day. d-dimer was associated with greater odds of next day delirium (OR, 1.49; 95% CI, 1.14–1.94; p < 0.01) and coma independently (OR, 1.52; 95% CI, 1.08–2.14; p = 0.017). Higher ferritin quartiles were associated with greater odds of next day delirium (OR, 1.33; 95% CI, 1.04–1.70; p = 0.026) and coma independently (OR, 1.59; 95% CI, 1.14–2.23; p < 0.01). Higher CRP quartiles were associated with coma (OR, 1.36; 95% CI, 1.03–1.79; p = 0.030) and delirium severity the next day (β = 0.30; se, 0.07; p ≤ 0.01). CONCLUSIONS: Our hypothesis-generating study found d-dimer and ferritin were associated with delirium/coma the following day, as well as delirium and coma independently. CRP was associated with next day coma and delirium severity. Larger studies to validate these results are needed.
Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.
Javle, Milind , Fonkoua, Lionel Aurelien Kankeu , Peng, Peng , Wang, Hui , Ngo, Brenda, Sun, Caixia, Ru, Qinhua, Wu, Frank, Fountzilas, Christos , Li, Daneng , Fan, Jean , Ngo, Brenda, Mahipal, Amit

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 539-539

10.1200/jco.2023.41.4_suppl.539 Get It

539 Background: Tinengotinib is a spectrum-selective multi-kinase inhibitor with a unique FGFR-binding mechanism. It potently inhibits FGFR2 fusion/rearrangement and acquired resistant mutations in pre-clinical models and early clinical studies in cholangiocarcinoma (CCA). Here we present the preliminary efficacy and safety of tinengotinib (TT-00420) in a phase II trial TT420C1206 (NCT04919642). Methods: Eligible patients (pts) with advanced/metastatic CCA exhausting standard treatment options received tinengotinib 10 mg QD. Pts were enrolled into four cohorts using historical FGFR alteration status: FGFR2 fusion(s) with primary progression on previous FGFR inhibitor (FGFRi) (A1) or progression after prior response to FGFRi (acquired resistance) (A2); non-fusion FGFR alteration(s) (B); or FGFR wild-type (FGFRwt, C). Primary endpoint was objective response rate (ORR) per RECIST version 1.1. Safety, PK parameters, and biomarker profile were evaluated and reviewed jointly with the efficacy outcomes. Adverse events (AEs) were graded per CTCAE version 5.0. Results: As of Sep 13, 2022, 25 pts with CCA were enrolled and dosed; 7 in A1, 6 in A2, 2 in B and 10 in C. Median age 61 [range 24-82] years old, 64% female, 93.3% had ≥ 3 prior treatment lines. 13 patients with ECOG 0 and 12 patients with ECOG 1 at baseline. Among 15 patients with historical FGFR alterations (13 fusions/rearrangement and 2 mutations), 93.3% had ≥ 1 prior FGFRi, and 3 pts (20.0%) had 2 prior FGFRi treatments. Eighteen pts were evaluable for tumor assessment at data cutoff date, including 4 in A1, 6 in A2, 1 in B and 7 in C. The median follow up was 15 weeks. In A2, 2 out of 6 pts (33%) achieved PR with tumor reductions of 34% and 54%. Overall DCR (CR or PR+SD) was 90% (9/10) in FGFR2 fusion/rearrangement pts; 100% in FGFR primary mutation pt (1/1); and 71% (5/7) in FGFRwt pts. One PR and 5 SDs lasted for more than 16 weeks. Among 25 treated pts, drug-related AEs occurred in 20 (80%) pts, including 7 (28%) with Grade (G) 1-2 AEs, 12 (48%) with G3 AEs, and 1 (4%) with G4 AE. Most frequently occurred G3/4 AEs were hypertension in 6 (24%) pts, including 5 (20%) with G3 and 1 (4%) with G4, G3 fatigue in 2 (8%) and G3 neutrophil count decreased in 2 (8%) pts. No drug-related G5 was observed. The efficacy and safety results observed were consistent with the previous reported data ( NCT03654547 ) in CCA pts. The preliminary biomarker analysis suggests loss of resistant FGFR mutation on liquid biopsy post tinengotinib therapy. Further biomarker analysis will be updated at the presentation. Conclusions: Tinengotinib may result in promising clinical benefit for CCA pts in the setting of FGFRi-resistance. Tinengotinib-related toxicities were manageable. An ongoing phase II study will further provide safety, efficacy and biomarker evaluations for both FGFR resistant and FGFRwt CCA. Clinical trial information: NCT04919642 .
Gene expression profiles in Hispanic patients with early-onset gastric cancer.
Ju, Michelle R. , Hwang, Tae Hyun , Hong, Changjin , Karalis, John D. , Hammer, Suntrea T.G. , Porembka, Matthew R , Wang, Sam C.

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 464-464

10.1200/jco.2023.41.4_suppl.464 Get It

464 Background: A larger proportion of Hispanic gastric cancer patients are diagnosed at a young age than patients of other ethnicities. Despite diagnosis at an early age, young Hispanic patients also present more frequently with advanced disease. Whether there are molecular differences between tumors from young and old Hispanic gastric cancer patients is unknown. Methods: We performed RNA-sequencing on pre-treatment tumor samples of gastric cancer patients of self-identified Hispanic ethnicity. We stratified patients into two groups: <50 years and ≥50 years. Differentially expressed genes between groups were detected using the DESeq2 package (RStudio). We performed Gene Set Enrichment Analysis (GSEA) to identify pathways that were uniquely overexpressed in each age group. Results: 57 patients were included in our study. 23 patients were <50 years and 33 patients were ≥50 years. Comparison of the top 10% most differentially expressed genes showed no clustering based on age. However, visual inspection of the top 40 most differentially expressed genes revealed 2 distinct patterns of gene expression between age groups. GSEA revealed upregulation of DNA replication, cell cycle, and DNA repair pathways in the younger patients The tumors in younger patients also had upregulation of multiple immune activation pathways. Cancers from older patients had upregulation of programmed cell death pathways. Conclusions: Early-onset gastric cancer in Hispanic patients may represent a distinct biologic process.
Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
Raymond, Eric, Hubner, Richard , Gotovkin, Evgeny, Pazo-Cid, Roberto , Kato, Ken, Tao, Aiyang, Peng, Yanyan , Li, Liyun , Yoon, Harry H. , Raymond, Éric , Wyrwicz, Lucjan , Cutsem, Eric Van , Jiménez‐Fonseca, Paula , Xu, Jianming , Wang, Lei

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 340-340

10.1200/jco.2023.41.4_suppl.340 Get It

340 Background: TIS, an anti-programmed cell death protein 1 (PD-1) antibody, + chemo as 1L therapy demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) vs PBO + chemo in patients with advanced or metastatic ESCC (hazard ratio [HR] 0.66 [95% confidence interval (CI) 0.54, 0.80]; P< 0.0001), with a manageable safety profile, at interim analysis of the phase 3, double-blind RATIONALE-306 study (NCT03783442). Here, we report data from the non-Asia subgroup (Europe, Northern America, and Oceania). Methods: Adults with advanced or metastatic ESCC, with no prior systemic treatment for advanced disease were randomized 1:1, (stratified by region, prior definitive therapy, and investigator [INV]-chosen chemo) to receive TIS 200 mg intravenously (IV) once every 3 weeks (Q3W) (Arm A) or PBO IV Q3W (Arm B), with platinum + fluoropyrimidine, or platinum + paclitaxel until disease progression by INV per RECIST v1.1, intolerable toxicity, or withdrawal. The primary endpoint was OS in the intent-to-treat population. Secondary endpoints included: progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) by INV per RECIST v1.1; OS in the programmed death-ligand 1 score ≥10%; and safety. Results: Of 649 randomized patients, 163 (25.1%) were from the non-Asia subgroup (Arm A, n = 83; Arm B, n = 80). At data cutoff (Feb 28, 2022), the median study follow-up time in the non-Asia subgroup was 16.0 months (mo) in Arm A vs 8.4 mo in Arm B. OS (median 16.3 vs 9.0 mo; unstratified HR 0.66 [95% CI 0.45, 0.96]) and PFS (median 7.7 vs 5.5 mo; unstratified HR 0.59 [95% CI 0.41, 0.83]) were improved in Arm A vs Arm B, respectively. Arm A had higher ORR (61.4% vs 41.3%, odds ratio 2.27 [95% CI 1.21, 4.25]) and longer median DoR (7.1 mo [95% CI 5.6, 9.6] vs 5.7 mo [95% CI 3.8, 8.3]) than Arm B. More patients in Arm A vs Arm B experienced ≥1 treatment-related adverse event (TRAE; 94.0% vs 88.5%), serious TRAEs (25.3% vs 17.9%), and discontinuation due to treatment-emergent AEs (42.2% vs 35.9%, respectively). Similar proportions of patients in Arm A vs Arm B had ≥grade 3 TRAEs (56.6% vs 52.6%), and TRAEs leading to death (1.2% vs 1.3%), respectively. Conclusions: In the non-Asia subgroup, 1L TIS + chemo showed a clinically meaningful improvement in OS vs PBO + chemo in patients with advanced or metastatic ESCC, with a manageable safety profile, consistent with published results in the overall population. Clinical trial information: NCT03783442 .
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
Sise, Meghan E. , Wang, Qiyu , Moreno, Daiana , Harden, Destiny , Smith, R. Neal , Rosales, Ivy A. , Chute, Sarah, Cornell, Lynn D. , Fadden, Riley, Sullivan, Ryan J. , Yang, Nancy, Barmettler, Sara , Wells, Sophia L., Reynolds, Kerry L. , Farmer, Jocelyn R. , Herrmann, Sandra M , Sullivan, Ryan J , Gupta, Shruti , Reynolds, Kerry L , Cornell, Lynn , Seethapathy, Harish Shanthanu , Colvin, Robert B. , Herrmann, Sandra M. , Gupta, Shruti , Villani, Alexandra–Chloé

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 19, 2023 | Volume: 11 | Issue: 1 | Pages: e006222

10.1136/jitc-2022-006222 | PMID 36657813 Get It

Background Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregulationpreviously defined in patients with congenital CTLA4 deficiency, including elevated soluble interleukin-2 receptor alpha (sIL-2R) and flow cytometric cell-based markers of B and T cell dysregulation in peripheral blood may aid the diagnosis of ICI-nephritis. Methods A retrospective cohort of patients diagnosed with ICI-nephritis was compared with three prospectively enrolled control cohorts: ICI-treated controls without immune-related adverse events, patients not on ICIs with hemodynamic acute kidney injury (hemodynamic AKI), and patients not on ICIs with biopsy proven acute interstitial nephritis from other causes (non-ICI-nephritis). sIL-2R level and flow cytometric parameters were compared between groups using Wilcoxon rank sum test or Kruskal-Wallis test. Receiver operating characteristic curves were generated to define the accuracy of sIL-2R and flow cytometric biomarkers in diagnosing ICI-nephritis. The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL2RA, IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared with other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls. Results sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal (ULN), IQR 1.9–3.3), compared with ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5–0.9, p<0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7–1.1, p=0.008). A sIL-2R cut-off point of 1.75-fold ULN was highly diagnostic of ICI-nephritis (area under the curve >96%) when compared with either ICI-treated or hemodynamic AKI controls. By peripheral blood flow cytometry analysis, lower absolute CD8+T cells, CD45RA+CD8+ T cells, memory CD27+B cells, and expansion of plasmablasts were prominent features of ICI-nephritis compared with ICI-treated controls. Gene expressions for IL2RA , IL-2 signaling, and T cell receptor signaling in the kidney tissue with ICI-nephritis were significantly higher compared with controls. Conclusion Elevated sIL-2R level and flow cytometric markers of both B and T cell dysregulation may aid the diagnosis of ICI-nephritis.
Fractionated plasma N‐glycan profiling of novel cohort of ATP6AP1‐CDG subjects identifies phenotypic association
Alharbi, Hana , Thies, Jenny , Chang, Irene J. , Goldner, Dana , Aqul, Amal , Velez‐Bartolomei, Frances , Enns, Gregory M. , Kichula, Elizabeth, Lee, Esther , Poskanzer, Sheri A. , Rasmussen, Sara K. , Saarela, Katelyn M. , Raymond, Kimiyo , Lam, Christina , Edmondson, Andrew C. , Lourenco, Charles , Poskanzer, Sheri A , Raymond, Kimiyo M, Freeze, Hudson H , Edmondson, Andrew C , Thies, Jenny M , Daniel, Earnest James Paul , Ng, Bobby G. , Witters, Peter , Hsu, Evelyn , Wang, YunZu Michele , Schultz, Matthew , Freeze, Hudson H. , He, Miao

Mayo Clinic

Journal of Inherited Metabolic Disease | January 18, 2023 | Volume: 46 | Issue: 2 | Pages: 300-312

10.1002/jimd.12589 | PMID 36651831 Get It

AbstractATP6AP1‐CDG is an X‐linked disorder typically characterized by hepatopathy, immunodeficiency, and an abnormal type II transferrin glycosylation pattern. Here, we present 11 new patients and clinical updates with biochemical characterization on one previously reported patient. We also document intrafamilial phenotypic variability and atypical presentations, expanding the symptomatology of ATP6AP1‐CDG to include dystonia, hepatocellular carcinoma, and lysosomal abnormalities on hepatic histology. Three of our subjects received successful liver transplantation. We performed N‐glycan profiling of total and fractionated plasma proteins for six patients and show associations with varying phenotypes, demonstrating potential diagnostic and prognostic value of fractionated N‐glycan profiles. The aberrant N‐linked glycosylation in purified transferrin and remaining plasma glycoprotein fractions normalized in one patient post hepatic transplant, while the increases of Man4GlcNAc2 and Man5GlcNAc2 in purified immunoglobulins persisted. Interestingly, in the single patient with isolated immune deficiency phenotype, elevated high‐mannose glycans were detected on purified immunoglobulins without glycosylation abnormalities on transferrin or the remaining plasma glycoprotein fractions. Given the diverse and often tissue specific clinical presentations and the need of clinical management post hepatic transplant in ATP6AP1‐CDG patients, these results demonstrate that fractionated plasma N‐glycan profiling could be a valuable tool in diagnosis and disease monitoring.
Exploring therapeutic strategies for infantile neuronal axonal dystrophy (INAD/PARK14)
Lin, Guang , Tepe, Burak , McGrane, Geoff, Tipon, Regine , Croft, Gist F. , Panwala, Leena, Hope, Amanda, Liang, Agnes JH, Zuo, Zhongyuan , Byeon, Seul Kee , Wang, Lily , Pandey, Akhilesh , Tipon, Regine C , Bellen, Hugo J , Pandey, Akhilesh , Byeon, Seul Kee , Bellen, Hugo J.

Mayo Clinic

eLife | January 16, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.82555 | PMID 36645408 Get It

Infantile neuroaxonal dystrophy (INAD) is caused by recessive variants in PLA2G6 and is a lethal pediatric neurodegenerative disorder. Loss of the Drosophila homolog of PLA2G6 , leads to ceramide accumulation, lysosome expansion, and mitochondrial defects. Here, we report that retromer function, ceramide metabolism, the endolysosomal pathway, and mitochondrial morphology are affected in INAD patient-derived neurons. We show that in INAD mouse models, the same features are affected in Purkinje cells, arguing that the neuropathological mechanisms are evolutionary conserved and that these features can be used as biomarkers. We tested 20 drugs that target these pathways and found that Ambroxol, Desipramine, Azoramide, and Genistein alleviate neurodegenerative phenotypes in INAD flies and INAD patient-derived neural progenitor cells. We also develop an AAV-based gene therapy approach that delays neurodegeneration and prolongs lifespan in an INAD mouse model.
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
Cameron, David , Bruzzone, Marco , Massarotti, Claudia , El-Abed, Sarra , Wang, Yingbo , Lecocq, Christophe, Rolyance, Rebecca, Sohn, Joohyuk , Arecco, Luca , Pistilli, Barbara , Ruddy, Kathryn J. , Saura, Cristina , Piccart, Martine , Cameron, David , El-Abed, Sarra , Sohn, Joohyuk , Saura, Cristina , Bruzzone, Marco , Lambertini, Matteo , Ceppi, Marcello , Anderson, Richard A. , Franzoi, Maria Alice , Nucíforo, Paolo , Pusztai, Lajos , Latocca, Maria Maddalena , Ballestrero, Alberto , Mastro, Lucia Del , Peccatori, Fedro A , Partridge, Ann H. , Untch, Michael , Cosimo, Serena Di , Azambuja, Evandro de , Demeestere, Isabelle

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 11, 2023 | Volume: 21 | Issue: 1 | Pages: 33-41.e16

10.6004/jnccn.2022.7065 | PMID 36634607 Get It

Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment–induced gonadotoxicity. Patients and Methods: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the “biological window” of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy). Results: The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33–42 years). AMH values at the 3 time points differed significantly (P<.001). At baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56–2.62 ng/mL). At week 2, a small but significant reduction in AMH levels was observed (median, 1.10 ng/mL; IQR, 0.45–2.09 ng/mL; P<.001). At surgery, a larger significant decline in AMH levels was observed (median, 0.01 ng/mL; IQR, 0.01–0.03 ng/mL; P<.001). Although the type of anti-HER2 treatment (trastuzumab and/or lapatinib) did not seem to impact the results, age and pretreatment ovarian reserve had a major influence on treatment-induced gonadotoxicity risk. Conclusions: This NeoALTTO biomarker analysis showed that anti-HER2 therapies alone had limited gonadotoxicity but that the addition of weekly paclitaxel resulted in marked AMH decline with possible negative implications for subsequent ovarian function and fertility.
Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer’s disease
Wheelock, Muriah D. , Strain, Jeremy F. , Mansfield, Patricia K. , Tu, Jiaxin Cindy , Tanenbaum, Aaron , Preische, Oliver, Chhatwal, Jasmeer P. , Cash, David M. , Fagan, Anne M. , Fox, Nick C. , Graff‐Radford, Neill R. , Hassenstab, Jason , Jack, Clifford R. , Xiong, Chengjie , Perrin, Richard J. , Xiong, Chengjie , Morris, John C. , Ances, Beau M. , Eggebrecht, Adam T. , Gordon, Brian A. , Network, the Dominantly Inherited Alzheimer, Adams, Sarah , Araki, Aki, Barthélemy, Nicolas R. , Bechara, Jacob , Berman, Sarah , Bodge, Courtney, Brandon, Susan E. , Brooks, W. K. , Brosch, Jared R. , Buck, Jill , Buckles, Virginia, Cash, Lisa, Chen, Charlie, Chrem, Patricio, Chua, Jasmin, Chui, Helena, Cruchaga, Carlos , Day, Gregory S. , Cruz, Chrismary De La, Denner, Darcy, Diffenbacher, Anna, Dincer, Aylin , Donahue, Tamara, Egido, Noelia , Esposito, Bianca, Farlow, Marty, Feldman, Becca , Fitzpatrick, Colleen , Franklin, Erin , Friedrichsen, Nelly, Gardener, Samantha L. , Goate, Alison , Goldberg, Sarah B. , Gonzalez, Alyssa, Gräber‐Sultan, Susanne, Graham, Morgan, Gray, Julia, Gremminger, Emily, Groves, Alex, Haass, Christian , Häsler, Lisa M., Hellm, Cortaiga, Herries, Elizabeth, Hoechst-Swisher, Laura, Hornbeck, Russ C. , Igor, Yakushev, Ihara, Ryoko , Ikonomović, Snežana, Ishii, Kenji , Jerome, Gina, Käser, Stephan, Keefe, Sarah , Klunk, William E. , Koudelis, Deb, Kuder-Buletta, Elke, Laske, Christoph , Martinez, Rita, Mason, Neal Scott, Mawuenyega, Kwasi G., Mejia, Arlene, Morenas‐Rodríguez, Estrella , Mori, Hiroshi , Mountz, James M. , Mummery, Cath, Nadkami, Neelesh, Nagamatsu, Akemi, Neimeyer, Katie, Norton, Joanne, Nuscher, Brigitte , Obermüller, Ulricke, Patira, Riddhi , Ping, Lingyan, Ringman, John M. , Salloway, Stephen , Senda, Michio , Seyfried, Nick , Shady, Kristine, Sigurdson, Wendy, Smith, Lori, Snitz, Beth E. , Sohrabi, Hamid R. , Stephens, Sochenda, Taddei, Kevin , Thompson, Sarah , Vöglein, Jonathan , Wang, Peter, Weamer, Elise A., Xu, Jinbin , Cruchaga, Carlos , Fagan, Anne M , Fox, Nick C , Graff-Radford, Neill R , Hassenstab, Jason , Jack, Clifford R , Karch, Celeste M , Xiong, Chengjie , McDade, Eric M , Schofield, Peter R , Xiong, Chengjie , Morris, John C , Bateman, Randall J , Jucker, Mathias , Benzinger, Tammie L S , Ances, Beau M , Eggebrecht, Adam T , Gordon, Brian A , Cruchaga, Carlos , Day, Gregory S , Vöglein, Jonathan , Cash, David M , Goate, Alison M , Berman, Sarah , Karch, Celeste M. , McDade, Eric , Schofield, Peter R. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, the Dominantly Inherited Alzheimer, Allegri, Ricardo , Brandon, Susan, Brooks, William (Bill), Buck, Jill, Carter, Kathleen, Douglas, Jane, Duong, Duc M , Feldman, Becca, Fitzpatrick, Colleen, Flores, Shaney , Fujii, Hisako , Ghetti, Bernardino , Goldman, Jill , Grilo, Miguel, Hofmann, Anna, Holtzman, David M. , Ikeuchi, Takeshi , Johnson, Erik C. B. , Kasuga, Kensaku , Koeppe, Robert A. , Lee, Jae‐Hong , Levey, Allan I. , Li, Yan , López, Oscar L. , Marsh, Jacob, Martins, Ralph N. , Masters, Colin L. , McCullough, Austin , Niimi, Yoshiki , Noble, James M. , O’Connor, Antoinette , Ping, Lingyan, Renton, Alan , Sánchez‐Valle, Raquel , Shimada, Hiroyuki , Smith, Jennifer A. , Thompson, Sarah, Wang, Qing , Xu, Xiong

Mayo Clinic

Brain | January 10, 2023 | Volume: 146 | Issue: 7 | Pages: 2928-2943

10.1093/brain/awac498 | PMID 36625756 Get It

Abstract Neurofilament light chain, a putative measure of neuronal damage, is measurable in blood and CSF and is predictive of cognitive function in individuals with Alzheimer’s disease. There has been limited prior work linking neurofilament light and functional connectivity, and no prior work has investigated neurofilament light associations with functional connectivity in autosomal dominant Alzheimer’s disease. Here, we assessed relationships between blood neurofilament light, cognition, and functional connectivity in a cross-sectional sample of 106 autosomal dominant Alzheimer’s disease mutation carriers and 76 non-carriers. We employed an innovative network-level enrichment analysis approach to assess connectome-wide associations with neurofilament light. Neurofilament light was positively correlated with deterioration of functional connectivity within the default mode network and negatively correlated with connectivity between default mode network and executive control networks, including the cingulo-opercular, salience, and dorsal attention networks. Further, reduced connectivity within the default mode network and between the default mode network and executive control networks was associated with reduced cognitive function. Hierarchical regression analysis revealed that neurofilament levels and functional connectivity within the default mode network and between the default mode network and the dorsal attention network explained significant variance in cognitive composite scores when controlling for age, sex, and education. A mediation analysis demonstrated that functional connectivity within the default mode network and between the default mode network and dorsal attention network partially mediated the relationship between blood neurofilament light levels and cognitive function. Our novel results indicate that blood estimates of neurofilament levels correspond to direct measurements of brain dysfunction, shedding new light on the underlying biological processes of Alzheimer’s disease. Further, we demonstrate how variation within key brain systems can partially mediate the negative effects of heightened total serum neurofilament levels, suggesting potential regions for targeted interventions. Finally, our results lend further evidence that low-cost and minimally invasive blood measurements of neurofilament may be a useful marker of brain functional connectivity and cognitive decline in Alzheimer’s disease.